Literature DB >> 26195941

St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.

Michael Gnant1, Christoph Thomssen2, Nadia Harbeck3.   

Abstract

The 2015 St. Gallen Consensus Conference on early breast cancer took place in Vienna, Austria, for the first time. After 3 days of high-level presentations by international panel members of clinical trials having been reported recently in the field, the traditional Saturday voting tried to translate the assembled knowledge into clinical treatment recommendations intended to guide clinical practice of breast cancer care for the 'average' patient. This report summarizes the results of the 2015 international panel voting procedures with respect to locoregional and endocrine treatment, chemotherapy, targeted therapy, as well as adjuvant bisphosphonate use. This report is not aimed to replace the official St. Gallen consensus publication - some recommendations may even be altered in the final paper - but should serve as a preliminary rapid report of this important meeting.

Entities:  

Keywords:  Axillary dissection; Bisphosphonates; Chemotherapy; Early breast cancer; Endocrine therapy; Neoadjuvant therapy; Radiotherapy; Surgery; Targeted therapy

Year:  2015        PMID: 26195941      PMCID: PMC4464099          DOI: 10.1159/000430488

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  12 in total

1.  Modern therapeutic concepts of early breast cancer.

Authors:  Michael Gnant
Journal:  Breast Care (Basel)       Date:  2014-05       Impact factor: 2.860

2.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.

Authors:  Cornelia Liedtke; Marc Thill; Volker Hanf; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

3.  Axillary Irradiation with High Tangent Fields for Clinically Node-Negative Breast Cancer: Can 3-D Conformal Radiotherapy with a Field-in-Field Technique Better Control the Axilla?

Authors:  Naoko Sanuki; Atsuya Takeda; Atsushi Amemiya; Toru Ofuchi; Masato Ono; Haruki Ogata; Ryo Yamagami; Jun Hatayama; Takahisa Eriguchi; Etsuo Kunieda
Journal:  Breast Care (Basel)       Date:  2013-10       Impact factor: 2.860

4.  Adjuvant ovarian suppression in premenopausal breast cancer.

Authors:  Prudence A Francis; Meredith M Regan; Gini F Fleming; István Láng; Eva Ciruelos; Meritxell Bellet; Hervé R Bonnefoi; Miguel A Climent; Gian Antonio Da Prada; Harold J Burstein; Silvana Martino; Nancy E Davidson; Charles E Geyer; Barbara A Walley; Robert Coleman; Pierre Kerbrat; Stefan Buchholz; James N Ingle; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Marco Colleoni; Giuseppe Viale; Alan S Coates; Aron Goldhirsch; Richard D Gelber
Journal:  N Engl J Med       Date:  2014-12-11       Impact factor: 91.245

Review 5.  Genomic profiling in triple-negative breast cancer.

Authors:  Cornelia Liedtke; Christof Bernemann; Ludwig Kiesel; Achim Rody
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

Review 6.  Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?

Authors:  Michael Knauer; Martin Filipits; Peter Dubsky
Journal:  Breast Care (Basel)       Date:  2014-05       Impact factor: 2.860

Review 7.  Local treatment of the axilla in early breast cancer: concepts from the national surgical adjuvant breast and bowel project B-04 to the planned intergroup sentinel mamma trial.

Authors:  Toralf Reimer; Steffi Hartmann; Angrit Stachs; Bernd Gerber
Journal:  Breast Care (Basel)       Date:  2014-05       Impact factor: 2.860

8.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

9.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321

10.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

View more
  31 in total

Review 1.  Biological Subtypes of Triple-Negative Breast Cancer.

Authors:  Michael Hubalek; Theresa Czech; Hannes Müller
Journal:  Breast Care (Basel)       Date:  2017-02-20       Impact factor: 2.860

2.  Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302).

Authors:  Judith O Hopkins; Jake Allred; Arti Hurria; Aminah Jatoi; Jacqueline M Lafky; Harvey Cohen; Clifford Hudis; Eric Winer; Jeanne Mandelblatt; Ann Partridge; Lisa Carey; Hyman B Muss
Journal:  Breast Cancer Res Treat       Date:  2017-08-20       Impact factor: 4.872

3.  Indian Solutions for Indian Problems-Association of Breast Surgeons of India (ABSI) Practical Consensus Statement, Recommendations, and Guidelines for the Treatment of Breast Cancer in India.

Authors:  S P Somashekhar; Gaurav Agarwal; S V S Deo; P Raghu Ram; Diptendra Sarkar; Vani Parmar
Journal:  Indian J Surg       Date:  2017-06-22       Impact factor: 0.656

4.  Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.

Authors:  Harindra Jayasekara; Robert J MacInnis; James A Chamberlain; Gillian S Dite; Nicole M Leoce; James G Dowty; Adrian Bickerstaffe; Aung Ko Win; Roger L Milne; Graham G Giles; Mary Beth Terry; Diana M Eccles; Melissa C Southey; John L Hopper
Journal:  Int J Cancer       Date:  2019-03-05       Impact factor: 7.396

5.  Digital quantification of KI-67 in breast cancer.

Authors:  María Del Rosario Taco Sanchez; Teresa Soler-Monsó; Anna Petit; Juan Azcarate; Alba Lasheras; Carmen Artal; Miguel Gil; Catalina Falo; María Jesús Pla; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2018-11-21       Impact factor: 4.064

6.  Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy.

Authors:  Nataliya Babyshkina; Marina Zavyalova; Natalia Tarabanovskaya; Tatyana Dronova; Nadejda Krakhmal; Elena Slonimskaya; Julia Kzhyshkowska; Evgeny Choynzonov; Nadejda Cherdyntseva
Journal:  Mol Cell Biochem       Date:  2017-12-11       Impact factor: 3.396

7.  Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.

Authors:  Allison W Kurian; Irina Bondarenko; Reshma Jagsi; Christopher R Friese; M Chandler McLeod; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Timothy P Hofer; Steven J Katz
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

Review 8.  St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.

Authors:  Michael Gnant; Nadia Harbeck; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2017-04-26       Impact factor: 2.860

Review 9.  Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women.

Authors:  Lorenzo Rossi; Olivia Pagani
Journal:  Curr Treat Options Oncol       Date:  2017-05

10.  Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer?

Authors:  Anusree Majumder; Rajat Jagani; Atoshi Basu
Journal:  Med J Armed Forces India       Date:  2019-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.